
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a leading global pharmaceutical company with a strong portfolio of prescription drugs and vaccines, and a significant presence in emerging markets. While the recent underperformance of the stock may pose a near-term challenge, Pfizer has a solid value proposition with potential upside driven by key assets such as Vyndaqel, which has the potential to generate $6 billion in peak sales. Additionally, the company's commitment to shareholder returns and a strong pipeline of new growth drivers further support a positive outlook for the stock.
Bears say
Pfizer is currently facing a number of challenges that could potentially impact its stock price and overall financial performance. These include a slower growth profile, higher exposure to loss of exclusivity for certain products, and a lower than average dividend payout ratio, which could limit the company's flexibility for mergers and acquisitions. Additionally, Pfizer is facing sustainability concerns related to access to medicines in lower income countries and potential environmental impacts from its manufacturing operations. These challenges could lead to a contraction in the company's price-to-earnings multiple and result in downside risks to its stock price.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares